PCI术后根据临床、缺血和出血风险比较抗血小板单药治疗
该研究为HOST-EXAM试验的事后分析,纳入5,403例PCI术后6-18个月无事件且接受双联抗血小板治疗的患者,随机比较氯吡格雷与阿司匹林单药治疗。结果显示氯吡格雷单药治疗的主要复合终点发生率低于阿司匹林单药治疗(HR 0.73,95%CI 0.59-0.90),且获益在不同临床风险、缺血和出血风险亚组中一致。
要点
- 氯吡格雷单药较阿司匹林单药降低主要复合终点风险(HR 0.73)。
- 无论TRS 2°P或DAPT评分高低,氯吡格雷获益一致。
- 临床可考虑PCI术后长期单药治疗优选氯吡格雷。
核心结论
- 氯吡格雷单药治疗在PCI术后患者中优于阿司匹林单药治疗,且获益不受临床风险、缺血和出血风险影响。
研究设计与样本
- HOST-EXAM试验的事后分析,随机分配PCI术后6-18个月无事件且接受DAPT的患者至氯吡格雷或阿司匹林单药治疗,共5,403例。
主要发现
- 氯吡格雷单药治疗的主要复合终点发生率低于阿司匹林单药治疗(HR 0.73;95%CI 0.59-0.90)。
- 高TRS 2°P(≥3)组HR 0.65(95%CI 0.44-0.96),低TRS 2°P(<3)组HR 0.77(95%CI 0.60-0.99),交互作用P=0.454。
- 高DAPT评分(≥2)组HR 0.68(95%CI 0.46-1.00),低DAPT评分(<2)组HR 0.75(95%CI 0.59-0.96),交互作用P=0.662。
- 单个结局的关联相似。
关键数值与推荐
- 主要复合终点为随机化后2年内的全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院和大出血(BARC≥3型)的复合终点。
- 风险分层使用DAPT评分和TRS 2°P(年龄≥75岁、糖尿病、高血压、当前吸烟、外周动脉疾病、卒中、冠脉搭桥、心力衰竭和肾功能不全之和)。
临床怎么用
- PCI术后长期抗血小板单药治疗可优先考虑氯吡格雷,尤其在高临床风险、缺血和出血风险患者中。
局限性
- 为事后分析,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clopidogrel was superior to aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI). OBJECTIVES: The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups METHODS: This was a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy) trial that randomly assigned patients who were event free for 6 to 18 months post-PCI on dual antiplatelet therapy (DAPT) to clopidogrel or aspirin monotherapy. Two clinical risk scores were used for risk stratification: the DAPT score and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) (the sum of age ≥75 years, diabetes, hypertension, current smoking, peripheral artery disease, stroke, coronary artery bypass grafting, heart failure, and renal dysfunction). The primary composite endpoint was a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission because of acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type ≥3) at 2 years after randomization. RESULTS: Among 5,403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy (HR: 0.73; 95% CI: 0.59-0.90). The benefit of clopidogrel over aspirin was consistent regardless of TRS 2°P (high TRS 2°P [≥3] group: HR: 0.65 [95% CI: 0.44-0.96]; and low TRS 2°P [<3] group: HR: 0.77 [95% CI: 0.60-0.99]) (P for interaction = 0.454) and regardless of DAPT score (high DAPT score [≥2] group: HR: 0.68 [95% CI: 0.46-1.00]; and low DAPT score [<2] group: HR: 0.75 [95% CI: 0.59-0.96]) (P for interaction = 0.662). The association was similar for the individual outcomes. CONCLUSIONS: The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy [HOST-EXAM]; NCT02044250).
引用
- Yang, Kang, Park, et al. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. J Am Coll Cardiol. 2023. PMID: 37821166. doi:10.1016/j.jacc.2023.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。